Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros











Tipo de estudio
Intervalo de año de publicación
1.
J Physiol Biochem ; 68(3): 411-20, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22351116

RESUMEN

We determined in cultured kidney epithelial cells (LLC-PK(1)) the effects of high glucose, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) on mRNA and protein expression of the renal glucose transporters SGLT1 and SGLT2. Cultured monolayers were incubated with similar concentrations of IL-6 and TNF-α to those produced by LLC-PK(1) in the presence of 20 mM glucose. Confluent monolayers with either 5 (controls, C) or 20 mM glucose (high glucose, HG) were incubated in the presence of 5 mM glucose, 20 mM glucose, 10 pg/ml IL-6, or TNF-α alone or in combination. Separate groups with IL-6 and TNF-α were incubated with antibodies to their respective receptors. HG induced an increased SGLT1 mRNA at 48 h (p<0.05 vs. C) and protein expression in 120 h (p<0.05 vs. C). HG also induced an increased SGLT2 mRNA at 72 and 96 h (P<0.05 vs. C) and SGLT2 protein expression at 120 h (p<0.05 vs. C). In C, 10 pg/ml IL-6 or TNF-α did not modify SGLT1 mRNA (n.s vs. in the absence of cytokines). In contrast, cytokines induced an increased expression of SGLT1 protein at 120 h (p<0.05 vs. in the absence of cytokines), and SGLT2 mRNA and protein were increased at 96 and 120 h, respectively (p<0.05 vs. in absence of cytokines). No changes were observed when cells were incubated with cytokines and HG (n.s vs. C). In conclusion, this study showed that SGLT2 increased in the presence of IL-6 and TNF-α, indicating an autocrine modulation of the expression of this transporter by cytokines.


Asunto(s)
Interleucina-6/farmacología , Transportador 2 de Sodio-Glucosa/genética , Factor de Necrosis Tumoral alfa/farmacología , Animales , Células Cultivadas , Proteínas Facilitadoras del Transporte de la Glucosa/genética , Proteínas Facilitadoras del Transporte de la Glucosa/metabolismo , Interleucina-6/metabolismo , ARN Mensajero/metabolismo , Transportador 1 de Sodio-Glucosa/genética , Transportador 1 de Sodio-Glucosa/metabolismo , Transportador 2 de Sodio-Glucosa/metabolismo , Porcinos/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo
2.
Brain Res ; 913(1): 78-81, 2001 Sep 14.
Artículo en Inglés | MEDLINE | ID: mdl-11532249

RESUMEN

Approximately 35% of HIV-infected subjects, both children and adults, exhibit alterations in the sleep-waking cycle. HIV surface glycoprotein gp120 has been postulated to contribute to this abnormality. For example, it has been reported that HIVgp120 modifies sleep in freely-moving rats and that it also activates the ERK pathway in brain slices. The goal of this work was to determine if sleep changes induced by HIVgp120 in normal rats are mediated by the MAPK pathway. Our results show that a single intraventricular administration of HIVgp120 selectively increases REMS and that such an increase can be prevented by U0126, an inhibitor of ERK activating enzyme, MEK. In contrast, SB202190, a MAPK-p38 inhibitor, had no effect on HIVgp120-induced increase in REMS. These results suggest that HIVgp120 increases REMS in the rat by specifically affecting the ERK signal transduction pathway.


Asunto(s)
Complejo SIDA Demencia/enzimología , Encéfalo/enzimología , Proteína gp120 de Envoltorio del VIH/farmacología , Sistema de Señalización de MAP Quinasas/fisiología , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Parasomnias del Sueño REM/enzimología , Sueño REM/fisiología , Complejo SIDA Demencia/fisiopatología , Complejo SIDA Demencia/virología , Animales , Encéfalo/efectos de los fármacos , Encéfalo/virología , Butadienos/farmacología , Interacciones Farmacológicas/fisiología , Inhibidores Enzimáticos/farmacología , Proteína gp120 de Envoltorio del VIH/metabolismo , Imidazoles/farmacología , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Masculino , Quinasas de Proteína Quinasa Activadas por Mitógenos/antagonistas & inhibidores , Quinasas de Proteína Quinasa Activadas por Mitógenos/metabolismo , Proteínas Quinasas Activadas por Mitógenos/antagonistas & inhibidores , Nitrilos/farmacología , Piridinas/farmacología , Parasomnias del Sueño REM/inducido químicamente , Parasomnias del Sueño REM/virología , Ratas , Ratas Wistar , Sueño REM/efectos de los fármacos , Vigilia/efectos de los fármacos , Vigilia/fisiología , Proteínas Quinasas p38 Activadas por Mitógenos
3.
Neurobiol Dis ; 7(4): 384-94, 2000 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-10964609

RESUMEN

Human immunodeficiency virus (HIV)-associated dementia (HAD) has been detected in 20-30% of patients suffering AIDS. The envelope glycoprotein 120 (gp120) derived from HIV seems to play a critical role in the pathophysiology of this dementia. Likewise, the feline immunodeficiency virus (FIV)-derived gp120 causes neurological and electrophysiological abnormalitites in cats. We have studied the effects of gp120 derived from HIV or FIV on learning and memory processing, hippocampal long-term potentiation (LTP), hippocampal neuronal cAMP production, the sleep-waking cycle, and locomotor activity and equilibrium in rats. Results showed that while both HIV- and FIV-gp120 impaired the rat's performance in the Barnes maze task, only HIVgp120 impaired the induction and maintenance of LTP. However, both glycoproteins induced a significant decrease in the posttetanic potentiation. HIVgp120 also caused a significant reduction in cAMP production in the hippocampus. Regarding the sleep-waking cycle, HIV- and FIV-gp120 increased the waking state and slow-wave sleep 1 (SWS1), while decreasing both SWS2 and REM sleep. Locomotor activity and equilibrium were significantly altered by these glycoproteins. These results suggest that HIVgp120 causes neurophysiological abnormalities and therefore may facilitate HAD development in AIDS patients.


Asunto(s)
Proteína gp120 de Envoltorio del VIH/farmacología , Virus de la Inmunodeficiencia Felina/inmunología , Memoria/efectos de los fármacos , Sueño/efectos de los fármacos , Complejo SIDA Demencia/fisiopatología , Animales , Antígenos Virales/farmacología , Gatos , Virus de la Inmunodeficiencia Felina/fisiología , Potenciación a Largo Plazo/efectos de los fármacos , Potenciación a Largo Plazo/fisiología , Masculino , Memoria/fisiología , Actividad Motora/efectos de los fármacos , Actividad Motora/fisiología , Ratas , Ratas Wistar , Sueño/fisiología
4.
Neuroreport ; 11(6): 1351-5, 2000 Apr 27.
Artículo en Inglés | MEDLINE | ID: mdl-10817620

RESUMEN

Between 20 and 30% of AIDS patients have neurological symptoms characterized by motor impairment, memory loss and progressive dementia. Previous studies have implicated the HIV derived gp120, which produces behavioral deficits and electrophysiological alterations in rats. The goal of the present study was to describe the effect of this protein on the P3 event-related potential (ERP), evoked by a passive discrimination task in rats. We used II rats divided into two groups: HIV gp120 (n = 6) and control (n = 5). We recorded the P3 wave before any treatment (baseline), during the i.c.v. administration of either HIVgp 120 (700 ng/5 days) or saline (pH 7.2), and 24 h, 7, 14 and 21 days after the last injection. There were no changes between groups in the amplitude or latencies of the observed components (N1, P2, N2 and P3) evoked by target stimuli, during baseline or during the injection period. However, the HIV gp120 group showed a significant amplitude reduction in P3 wave 24 h after the last injection, while the N1, P2 and N2 waves remained unchanged. However, from the 7th day through the 21st day, P2 and N2 components also disappeared and only the N1 component could be observed in the HIV gp 20-treated group. These changes in the N2, P2 and P3 potentials, suggesting an alteration in cognitive processes, further support the neurotoxic activity of HIV gp120 and its role in AIDS dementia.


Asunto(s)
Complejo SIDA Demencia/fisiopatología , Aprendizaje Discriminativo/efectos de los fármacos , Potenciales Evocados/efectos de los fármacos , Proteína gp120 de Envoltorio del VIH/farmacología , Complejo SIDA Demencia/inducido químicamente , Estimulación Acústica , Animales , Conducta Animal/efectos de los fármacos , Electroencefalografía/efectos de los fármacos , Potenciales Evocados/fisiología , Potenciales Evocados Auditivos del Tronco Encefálico/efectos de los fármacos , Inyecciones Intraventriculares , Masculino , Ratas , Ratas Wistar , Tiempo de Reacción/efectos de los fármacos
5.
Behav Brain Res ; 57(1): 1-7, 1993 Oct 21.
Artículo en Inglés | MEDLINE | ID: mdl-8292248

RESUMEN

It has been proposed that functions associated with the prefrontal cortex could change as a consequence of aging. Previous experiments in young rats have demonstrated that anatomical lesions or chronic GABA infusions into this area produce deficits in spatial delayed alternation tasks. The present study examines the effect of chronic (7 days) GABA or saline infusion into the prefrontal cortex on the performance of delayed alternation task in old rats (24 months). The results suggested that aged rats needed more sessions to acquire the delayed alternation task. GABA infusions into the prefrontal cortex produced deficits in spatial alternation tasks similar to those previously observed in young rats. Performance rapidly recovered after the infusion period. Histological analysis showed similar lesion size in both groups. The results suggest that aged prefrontal cortex and/or related areas participating in the acquisition of the delayed alternation task are more sensitive to aging processes. Furthermore, the prefrontal cortex is important for the retention of a previously learned spatial delayed alternation task. The structures involved in functional recovery from these deficits appear to be fully functional in aged rats.


Asunto(s)
Envejecimiento/efectos de los fármacos , Aprendizaje Discriminativo/efectos de los fármacos , Recuerdo Mental/efectos de los fármacos , Orientación/efectos de los fármacos , Corteza Prefrontal/efectos de los fármacos , Solución de Problemas/efectos de los fármacos , Ácido gamma-Aminobutírico/farmacología , Envejecimiento/fisiología , Animales , Conducta Apetitiva/efectos de los fármacos , Conducta Apetitiva/fisiología , Atención/efectos de los fármacos , Atención/fisiología , Mapeo Encefálico , Aprendizaje Discriminativo/fisiología , Habituación Psicofisiológica/efectos de los fármacos , Habituación Psicofisiológica/fisiología , Bombas de Infusión Implantables , Masculino , Recuerdo Mental/fisiología , Orientación/fisiología , Corteza Prefrontal/fisiología , Solución de Problemas/fisiología , Ratas , Ratas Wistar , Tiempo de Reacción/efectos de los fármacos , Tiempo de Reacción/fisiología , Ácido gamma-Aminobutírico/fisiología
8.
Salud pública Méx ; 23(6): 607-611, 1981.
Artículo en Español | LILACS | ID: lil-11620

RESUMEN

Se analizan los resultados obtenidos con la vacuna pertussis producida durante nueve anos en cultivo estacionario, utilizando las cepas 10536, 18334 y 18904 procedente de Michigan; y cinco anos en cultivo sumergido utilizando las cepas 509 y 134 procedentes de Holanda. Se logro un gran incremento de la produccion usando la fermentacion. La potencia de las vacunas fue determinada por el metodo de Kendrick (proteccion activa en el raton). El promedio de los resultados obtenidos fue de 13.75 UP/ml en cultivo estacionario y 10.51 UP/ml en cultivo por fermentacion.Aplicando la prueba de t se concluye que la diferencia de resultados es altamente significativa. Por otro lado y basandose en la dispersion de los resultados, puede afirmarse que con el metodo de fermentacion se obtiene menor variacion en la potencia de los lotes


Asunto(s)
Vacuna contra la Tos Ferina , Medios de Cultivo , Fermentación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA